Single-arm phase 2 study | Lenvatinib plus Pembrolizumab for melanoma with confirmed progression on a PD-1 or PD-L1 inhibitor given as monotherapy or in combination.

Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination – Journal of Clinical Oncology (link to abstract – $ for full-text)

Commentary: TKI Plus Immunotherapy Active in Melanoma After Anti-PD-1 Progression — More than a fifth of patients responded to lenvatinib-pembrolizumab combination – MedPage Today (free registration required)